On Aug 23, 2021 Elixiron Immunotherapeutics closed a Series A round and raised $27,000,000 from China Development Industrial Bank (CDIB), DCI Partners, Fubon Financial Holdings, Mega International Commercial Bank, Pangu Venture Capital, Taiwania Capital, featuring lead investors Pangu Venture Capital, Taiwania Capital.

About the company: Elixiron Immunotherapeutics is located at Taiwan, Asia.
“Elixiron Immunotherapeutics”

Company website: www.elixiron.com/